A review of 12 studies about AI systems used to screen patients for breast cancer found that they lacked evidence to prove that they would work well in a clinical setting. Researchers highlighted concerns about study quality, including the fact that all of the studies were retrospective and many of them had a high risk of bias.
The decision to or to not get a mammogram for women can be challenging based on increasing information about risks, especially when financial incentives are involved.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
We all know that most medical treatments have potential side effects, some more than others of course. But it can be difficult to break down and conceptualize the numbers as far as determining if certain therapies will do more harm than good. That’s where Number Needed to Treat, or N.N.T. and Number Needed to Harm N.N.H. […]
A breast cancer diagnostics startup that offers an ancillary imaging system to use on top of standard mammography just raised $6.5 million, according to regulatory filings. New Hampshire-based Gamma Medica has developed a tool, called the LumaGEM, that’s meant as a secondary diagnostic tool for women with dense breast tissue. It’s more difficult for mammograms to discern the […]
The British Medical Journal published a monumental study on screening mammography this week. It’s garnered a ton of media coverage because the findings provocatively question the sacrosanct idea that early detection of breast cancer saves lives. Imagine that…Imagine if the entire pink machine was misguided. Of course, for people who have been willing to squint […]